title: Nanoformulation strategies for the enhanced oral bioavailability of antiretroviral therapeutics.
abstract: The oral delivery of drugs with poor aqueous solubility is challenging and often results in poor bioavailability. Various nanoformulation platforms have demonstrated improved oral bioavailability of a range of drugs for different indications. The focus of this review is to provide an overview of the application of nanomedicine to oral antiretroviral therapy and outline how the current short-falls of this life-long therapy may be resolved using nanotechnology. As well as highlighting the rationale for a nanomedicine-based approach, the review focuses on the various strategies used to enhance oral bioavailability and describes the mechanisms of particle absorption across the GI tract. The recent advances in the development of long-acting formulations for both HIV treatment and pre-exposure prophylaxis are also discussed.
authors.affiliation: Department of Molecular & Clinical Pharmacology, University of Liverpool, 70 Pembroke Place, Block H (First Floor), Liverpool, L69 3GF, UK.
authors.forename: Lee M
authors.initials: LM
authors.lastname: Tatham
authors.forename: Steven P
authors.initials: SP
authors.lastname: Rannard
authors.forename: Andrew
authors.initials: A
authors.lastname: Owen
mesh_terms: D000284:Administration, Oral; D044966:Anti-Retroviral Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D001682:Biological Availability; D002626:Chemistry, Pharmaceutical / Q000379:methods*; D003692:Delayed-Action Preparations / Q000627:therapeutic use; D065569:Gastrointestinal Absorption; D015658:HIV Infections / Q000188:drug therapy / Q000517:prevention & control; D006801:Humans; D050997:Nanomedicine / Q000379:methods*
chemical_list: D044966:Anti-Retroviral Agents; D003692:Delayed-Action Preparations